Caris Life Sciences Validates AI Model for Temozolomide Response in Glioblastoma
Caris Life Sciences has published a peer-reviewed study validating its AI-based predictive signature for temozolomide benefit in glioblastoma patients, showing strong concordance with traditional MGMT methylation testing.